Despite trading at low multiples, Viatris is exposed to macroeconomic headwinds, regulatory pressures, and a $500M revenue hit from FDA actions, increasing downside risk. Recent impairments and the ...
Both Alvotech ALVO and Teva Pharmaceuticals TEVA operate in the biosimilar space, but their business models differ significantly. ALVO has built its revenue model around partnerships, relying on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results